{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Plaque%2C+Amyloid&page=2",
    "query": {
      "condition": "Plaque, Amyloid",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Plaque%2C+Amyloid&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-07-22T05:49:29.390Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00544453",
      "title": "Evaluation of [123I] MNI-308 and SPECT as a Marker of Beta-amyloid Protein Deposition in AD Subjects Compared to HC",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Alzheimer Disease"
      ],
      "interventions": [
        {
          "name": "[123I] MNI-308",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Molecular NeuroImaging",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 2,
      "start_date": "2007-10",
      "completion_date": "2008-07",
      "has_results": false,
      "last_update_posted_date": "2009-08-21",
      "last_synced_at": "2026-07-22T05:49:29.390Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00544453"
    },
    {
      "nct_id": "NCT05521919",
      "title": "Acute Plasma Abeta Responses to Stress",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Stress Reaction",
        "Stress Physiology"
      ],
      "interventions": [
        {
          "name": "Sympathetic Nervous System Activation",
          "type": "BEHAVIORAL"
        },
        {
          "name": "No-stress",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "University of Southern California",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 38,
      "start_date": "2023-12-05",
      "completion_date": "2024-12-10",
      "has_results": false,
      "last_update_posted_date": "2025-12-10",
      "last_synced_at": "2026-07-22T05:49:29.390Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05521919"
    },
    {
      "nct_id": "NCT06244303",
      "title": "Clinical Research Study to Assess the Efficacy of Two Brushing Regimens in the Reduction of Established Dental Plaque and Gingivitis.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Gingivitis",
        "Plaque"
      ],
      "interventions": [
        {
          "name": "manual Tooth Brush + Colgate Total TP (0.454% SnF, 1100 ppm F)",
          "type": "DRUG"
        },
        {
          "name": "manual toothbrush + Colgate dental cream",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Colgate Palmolive",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 82,
      "start_date": "2024-01-22",
      "completion_date": "2024-04-16",
      "has_results": false,
      "last_update_posted_date": "2026-03-19",
      "last_synced_at": "2026-07-22T05:49:29.390Z",
      "location_count": 1,
      "location_summary": "Costa Mesa, California",
      "locations": [
        {
          "city": "Costa Mesa",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06244303"
    },
    {
      "nct_id": "NCT01806597",
      "title": "Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Palmoplantar Psoriasis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Moderate to Severe Palmoplantar Psoriasis"
      ],
      "interventions": [
        {
          "name": "secukinumab 150 mg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "secukinumab 300 mg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 205,
      "start_date": "2013-06-19",
      "completion_date": "2016-11-02",
      "has_results": true,
      "last_update_posted_date": "2018-02-22",
      "last_synced_at": "2026-07-22T05:49:29.390Z",
      "location_count": 8,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Indianapolis, Indiana + 5 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01806597"
    },
    {
      "nct_id": "NCT03070535",
      "title": "APOE Genotype and Diet Influences on Alzheimer's Biomarkers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Alzheimer's Disease; Dementia"
      ],
      "interventions": [
        {
          "name": "HIGH and LOW meal ingestion",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "University of Washington",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "55 Years and older"
      },
      "enrollment_count": 78,
      "start_date": "2016-09",
      "completion_date": "2023-03-30",
      "has_results": false,
      "last_update_posted_date": "2024-03-13",
      "last_synced_at": "2026-07-22T05:49:29.390Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03070535"
    },
    {
      "nct_id": "NCT03954210",
      "title": "SIESTA: Sleep Intervention to Enhance Cognitive Status and Reduce Beta Amyloid",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Insomnia"
      ],
      "interventions": [
        {
          "name": "Cognitive Behavioral Therapy for Insomnia (CBT-I)",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Sleep and Lifestyle Education",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "University of Kansas Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "60 Years to 85 Years"
      },
      "enrollment_count": 200,
      "start_date": "2019-08-27",
      "completion_date": "2025-04-18",
      "has_results": true,
      "last_update_posted_date": "2026-03-27",
      "last_synced_at": "2026-07-22T05:49:29.390Z",
      "location_count": 1,
      "location_summary": "Kansas City, Kansas",
      "locations": [
        {
          "city": "Kansas City",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03954210"
    },
    {
      "nct_id": "NCT05283135",
      "title": "High Dose Risankizumab for Psoriasis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Psoriasis"
      ],
      "interventions": [
        {
          "name": "risankizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Oregon Medical Research Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2022-03-01",
      "completion_date": "2024-07-10",
      "has_results": true,
      "last_update_posted_date": "2025-10-24",
      "last_synced_at": "2026-07-22T05:49:29.390Z",
      "location_count": 1,
      "location_summary": "Portland, Oregon",
      "locations": [
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05283135"
    },
    {
      "nct_id": "NCT02033668",
      "title": "Pharmacokinetic (PK) Study of GSK933776 in Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Atrophy, Geographic"
      ],
      "interventions": [
        {
          "name": "GSK933776 for SQ administration",
          "type": "DRUG"
        },
        {
          "name": "GSK933776 for IM administration",
          "type": "DRUG"
        },
        {
          "name": "GSK933776 for IV administration",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 36,
      "start_date": "2014-01-22",
      "completion_date": "2014-07-15",
      "has_results": false,
      "last_update_posted_date": "2017-05-15",
      "last_synced_at": "2026-07-22T05:49:29.390Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02033668"
    },
    {
      "nct_id": "NCT01490632",
      "title": "A Phase 2b Study of Baricitinib in Participants With Moderate to Severe Psoriasis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Psoriasis",
        "Skin Diseases",
        "Skin Diseases, Papulosquamous"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Baricitinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 271,
      "start_date": "2011-12",
      "completion_date": "2014-08",
      "has_results": true,
      "last_update_posted_date": "2019-09-27",
      "last_synced_at": "2026-07-22T05:49:29.390Z",
      "location_count": 18,
      "location_summary": "Bakersfield, California • Santa Monica, California • Miami, Florida + 15 more",
      "locations": [
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Miramar",
          "state": "Florida"
        },
        {
          "city": "Ocala",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01490632"
    },
    {
      "nct_id": "NCT05834296",
      "title": "Study in Subjects With Mild-to-Moderate Alzheimer's Dementia",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Alzheimer Disease"
      ],
      "interventions": [
        {
          "name": "ALZN002 (autologous DCs pulsed with E22W mutant peptide).",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Alzamend Neuro, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "60 Years to 85 Years"
      },
      "enrollment_count": 30,
      "start_date": "2023-07-05",
      "completion_date": "2028-03-03",
      "has_results": false,
      "last_update_posted_date": "2025-09-02",
      "last_synced_at": "2026-07-22T05:49:29.390Z",
      "location_count": 1,
      "location_summary": "Doral, Florida",
      "locations": [
        {
          "city": "Doral",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05834296"
    }
  ]
}